Treatment with BB-Cl-amidine subtly reduces splenomegaly in MRL/lpr mice, while there is a trend towards increased circulating levels of anti-NET antibodies with PAD inhibitor treatment. However, neither PAD inhibitor affected body weight or total IgG levels. In fact, treatment with both Cl-amidine and BB-Cl-amidine significantly improves endothelium-dependent vasorelaxation. The BB-Cl-amidine group also shows a strong trend towards downregulation of IRGs. Treatment with either Cl-amidine or BB-Cl-amidine significantly improves muzzle alopecia, in many cases preventing it entirely [1]. Animal Model: MRL/lpr mice [1]. Dosage: 1 mg/kg. Administration: Subcutaneous injection daily from 8 to 14 weeks of age. Result: Significantly improved endothelium-dependent vasorelaxation and showed a strong trend towards downregulation of IRGs.